Association of genetic polymorphism -670A>G in the Fas gene and serum markers AST platelet ratio index, AST/ALT with significant fibrosis and cirrhosis in chronic hepatitis C

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 6, 2012, Pages 531-535

  Deghady, Akram ^a   Abdou, Alaa ^a   El Neanaey, Wafaa Ahmed ^a   Diab, Iman ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FAS ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; GUANINE; HEMOGLOBIN; SERUM ALBUMIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; SENSITIVITY ANALYSIS; THROMBOCYTE COUNT;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIGENS, CD95; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; POLYMORPHISM, GENETIC;

HEPATITIS C VIRUS;

EID: 84862977626     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0098     Document Type: Article

References (24)

1. Anguilar-Reina J, Ruiz-Ferrer M, Pizarro MA (2005) The - 670A >G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C. J Viral Hepatol 12:568-573.
2. Carey E, Carey WD (2010) Non invasive tests for liver disease, fibrosis and cirrhosis: is liver biopsy obsolete? Cleve Clin J Med 77:519-527.
3. Chen-Sheng L, Chi-Sen Chang, Sheng-Shun Yang (2008) Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Inter Med 47:569-575.
4. Colloredo G, Guido M, SonzogniA, et al. (2003) Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatology 39:239-244. (Pubitemid 36920560)
5. Eduardo SL, Adriana FF, Fernando LG(2007) Non invasive means of diagnostic liver fibrosis in hepatitis C. BJID 11:530-533.
6. Farci P, Alter HJ, Govindarajian S (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135-140.
7. Farre L, Bittencourt AL, Silva-Santos G, et al. (2008) Fas-670 promoter polymorphism is associated to susceptibitliy, clinical presentation & survival in adult Tcell leukemia. J Leukoc Biol 83:220-222.
8. Gebo KA, Herong HF, Torbenson MS, et al. (2002) Role of liver biopsy in management of chronic hepatitis C.A systematic review. J Hepatol 36:s161-s172. (Pubitemid 35253477)
9. Hiramatsu N, Hayashi N, Katayama K, et al. (1997) Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. J Hepatol 19:1345-1359.
10. Hubscher SG (1998) Histologic grading and staging in chronic hepatitis: clinical applications and proplems. J Hepatol 29: 1015-1022.
11. Jarmay K, Karacsony G, Ozsvar Z, et al. (2002) Assessment of histological features in chronic hepatitis C. Hepatogastroenterol 49:239-243. (Pubitemid 34289527)
12. Kanemitsu S, Ihara K, Saifddin A, et al. (2002) A functional polymorphism in Fas (CD95/Apo-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 29: 1183-1188. (Pubitemid 34601951)
13. Mcllroy D, TheodorouI, Ratziu V, et al. (2005) Fas promoter polymorphisms correlate with activity grade in hepatitis C patients. Eur J Gastroentrol Hepatol 17:1081-1088. (Pubitemid 41424002)
14. Parise ER, Oliveira AC, Figueiredo-Mendes C (2006) Non invasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 26:1095-1099. (Pubitemid 44548838)
15. Ruggier A, HaradaT, MatsuraY, et al. (1997) Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 229:68-76. (Pubitemid 27243489)
16. Shigeka Zu Nagata, Pierre Golstein (1995) The Fas death factor. Science 10:1449-1455.
17. Shin JY, Hur W, Wang JS, et al. (2005) HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med 37:138-145. (Pubitemid 40676924)
18. Sibley K, Rollinson S, Allan JM et al. (2003) Functional Fas promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327-4330. (Pubitemid 36950998)
19. Tobi E, Kessel A, Goldstein L (2001) Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: association with liver disease severity. J Hepatol 35:774-780. (Pubitemid 34717669)
20. Van Veen T, Kalkers NF, Crusius JB, et al. (2002) The Fas-670 polymorphism influences susceptibility to multiple sclerosis. J Neuroimmunol 128:95-100. (Pubitemid 34722369)
21. Waked IA, Saleh SN, Moustafa MS (1995) High prevalence of hepatitis C virus in Egyptian patients with chronic liver disease. Gut 37:105-107.
22. Wallach J (2000) Interpretation of Diagnostic Tests, 7th edition. Williams and Wilkins, Philadelphia, PA.
23. Wasely A, Iter MJ (2000) Epidemiology of hepatitis C: geographic difference and temporal trends. Semin Liver Dis 20:1-16.
24. Wong JB, Koff RS (2000) Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost- effectiveness analysis. Ann Intern Med 133:665-675.